Log in

NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News

$4.85
-0.12 (-2.41 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.85
$5.25
50-Day Range
$4.80
MA: $7.21
$9.58
52-Week Range
$4.56
Now: $4.85
$17.34
Volume93,859 shs
Average Volume136,737 shs
Market Capitalization$88.59 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome. The company is based in Ann Arbor, Michigan.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MLND
CUSIPN/A
CIKN/A
Phone734-845-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Book Value$3.28 per share

Profitability

Net Income$-44,570,000.00

Miscellaneous

Employees32
Market Cap$88.59 million
Next Earnings Date5/20/2020 (Estimated)
OptionableNot Optionable

Receive MLND News and Ratings via Email

Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.


Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions

How has Millendo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MLND stock has decreased by 26.3% and is now trading at $4.85. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics.

When is Millendo Therapeutics' next earnings date?

Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Millendo Therapeutics.

How were Millendo Therapeutics' earnings last quarter?

Millendo Therapeutics Inc (NASDAQ:MLND) issued its earnings results on Wednesday, March, 11th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.81) by $0.06. View Millendo Therapeutics' earnings history.

What price target have analysts set for MLND?

7 Wall Street analysts have issued 12 month price objectives for Millendo Therapeutics' shares. Their forecasts range from $20.00 to $35.00. On average, they expect Millendo Therapeutics' share price to reach $25.33 in the next year. This suggests a possible upside of 422.3% from the stock's current price. View analysts' price targets for Millendo Therapeutics.

Has Millendo Therapeutics been receiving favorable news coverage?

News coverage about MLND stock has been trending very negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMillendo Therapeutics.

Are investors shorting Millendo Therapeutics?

Millendo Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 266,300 shares, an increase of 67.5% from the February 27th total of 159,000 shares. Based on an average daily trading volume, of 226,000 shares, the days-to-cover ratio is currently 1.2 days. Currently, 2.7% of the shares of the stock are sold short. View Millendo Therapeutics' Current Options Chain.

Who are some of Millendo Therapeutics' key competitors?

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Gilead Sciences (GILD), Roku (ROKU), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Applied Genetic Technologies (AGTC), Aravive (ARAV), Avid Bioservices (CDMO), Novavax (NVAX) and OrganiGram (OGI).

Who are Millendo Therapeutics' key executives?

Millendo Therapeutics' management team includes the following people:
  • Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 45)
  • Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory Board
  • Mr. Louis J. Arcudi III, MBA, Chief Financial Officer (Age 58)
  • Mr. Jeffery M. Brinza J.D., Chief Admin. Officer, Gen. Counsel & Sec. (Age 57)
  • Dr. Pharis Mohideen, Chief Medical Officer (Age 54)

What is Millendo Therapeutics' stock symbol?

Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND."

How do I buy shares of Millendo Therapeutics?

Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Millendo Therapeutics' stock price today?

One share of MLND stock can currently be purchased for approximately $4.85.

How big of a company is Millendo Therapeutics?

Millendo Therapeutics has a market capitalization of $88.59 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 32 workers across the globe. View additional information about Millendo Therapeutics.

What is Millendo Therapeutics' official website?

The official website for Millendo Therapeutics is http://www.millendo.com/.

How can I contact Millendo Therapeutics?

Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected]

This page was last updated on 4/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel